Method for preventing or treating M tuberculosis infection

• US 10,350,283 B2
• Filed: 09/19/2018
• Issued: 07/16/2019
• Est. Priority Date: 04/29/2005
• Status: Expired due to Fees

• Current Assignee: Glaxosmithkline Biologicals SA (GlaxoSmithKline PLC)
• Original Assignee: Glaxosmithkline Biologicals SA (GlaxoSmithKline PLC)
• Inventors: Marchand, Martine
• Primary Examiner(s): Swartz, Rodney P
• Application Number:
  US16/135,553
• Publication Number:
  US 20190030154A1
• Time in Patent Office: 300 Days
• Field of Search: 4241841, 4241851, 4242341, 4242481, 536 231, 536 235
• CPC Class Codes: A61K 2039/523 expressing foreign proteins
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/55572 Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• CPC Class Codes: A61K 2039/55577 Saponins; Quil A; QS21; ISCOMS
• CPC Class Codes: A61K 2039/575 humoral response
• CPC Class Codes: A61K 31/4409 only substituted in position 4, e.g. isoniazid, iproniazid
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 39/04 Mycobacterium, e.g. Mycobacterium tuberculosis
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/35 from Mycobacteriaceae (F)

Abstract

The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Claims

1. A polynucleotide comprising a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:

4.

2. The polynucleotide according to claim 1, comprising the nucleic acid sequence of SEQ ID NO:

3.

3. A pharmaceutical composition comprising the polynucleotide according to claim 2, wherein the polynucleotide is provided in a viral vector.

4. A pharmaceutical composition, comprising the polynucleotide according to claim 2 wherein the polynucleotide is provided in a bacterium host cell.

5. The pharmaceutical composition according to claim 4, wherein the bacterium host cell is Bacillus Calmette-Guerin.